Demant A/S (OTCMKTS:WILYY) Downgraded to “Hold” Rating by UBS Group

Demant A/S (OTCMKTS:WILYY) was downgraded by analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Several other brokerages also recently issued reports on WILYY. Morgan Stanley raised shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. Zacks Research upgraded Demant A/S to a “hold” rating in a research report on Friday, June 26th. Finally, Sanford C. Bernstein downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Demant A/S Price Performance

OTCMKTS:WILYY opened at $20.66 on Wednesday. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36. The firm has a 50-day moving average price of $19.59 and a two-hundred day moving average price of $16.95. Demant A/S has a twelve month low of $13.45 and a twelve month high of $20.98.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.